Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Abiraterone + XmAb20717 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 54 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
XmAb20717 | XmAb 20717|Vudalimab | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | XmAb20717 (Vudalimab) is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05733351 | Phase I | Abiraterone + XmAb20717 Enzalutamide + XmAb20717 Abiraterone + Docetaxel + XmAb20717 | Vudalimab in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | Suspended | USA | 0 |